canin
infecti
respiratori
diseas
cird
also
known
kennel
cough
common
diseas
syndrom
particularli
preval
within
larg
dog
popul
train
kennel
cird
repres
major
welfar
issu
kennel
facil
pet
owner
veterinarian
global
outbreak
result
delay
train
expens
treatment
cost
characteris
clinic
sign
cough
nasal
discharg
dyspnoea
persist
sever
week
may
result
sever
diseas
bronchopneumonia
even
occas
lead
death
euthanasia
akin
respiratori
syndrom
cattl
bovin
respiratori
diseas
complex
pig
porcin
respiratori
diseas
complex
cird
complex
infect
multifactori
aetiolog
multipl
pathogen
act
sequenti
synergist
caus
diseas
addit
environment
factor
age
stress
underli
health
problem
also
contribut
diseas
spread
suscept
kennel
dog
particularli
risk
cird
high
popul
densiti
shelter
often
constant
influx
suscept
anim
pathogen
compound
situat
pathogen
tradit
associ
cird
includ
canin
parainfluenza
viru
cpiv
canin
adenoviru
type
canin
herp
viru
bordetella
bronchiseptica
bb
spread
aerosolis
droplet
cough
sneez
contact
fomit
present
item
bed
bowl
cloth
method
prevent
cird
includ
good
biosecur
quarantin
new
sick
anim
high
level
sanit
efficaci
vaccin
often
howev
shelter
space
implement
quarantin
procedur
busi
kennel
environ
maintain
high
level
sanit
challeng
thu
vaccin
vital
manag
diseas
sever
multival
vaccin
avail
tabl
howev
widespread
anecdot
recognit
current
vaccin
often
fail
prevent
cird
spark
resurg
interest
prevent
diseas
stimul
studi
centr
pathogen
identif
surveil
manag
find
import
implic
futur
cird
vaccin
design
perhap
import
find
number
newli
emerg
pathogen
identifi
cird
outbreak
novel
agent
includ
canin
respiratori
coronaviru
crcov
canin
pneumoviru
cnpnv
canin
influenza
viru
civ
canin
coronaviru
streptococcu
zooepidemicu
mycoplasma
cyno
subject
recent
review
except
civ
vaccin
recent
licens
usa
novel
agent
current
target
vaccin
like
play
import
role
develop
persist
cird
otherwis
kennel
obviou
target
futur
vaccin
develop
process
consid
novel
cird
vaccin
first
review
paper
focu
immunolog
mechan
provid
protect
respiratori
tract
current
recommend
canin
vaccin
importantli
challeng
surround
exist
cird
vaccin
futur
develop
highlight
within
review
lack
publish
data
within
field
hamper
cird
vaccin
develop
hope
rais
question
best
address
futur
major
protect
immun
mucosa
mediat
humor
branch
adapt
immun
respons
specif
secret
antibodi
iga
siga
product
type
cytokin
eg
interleukin
il
transform
growth
factor
th
cell
stimul
matur
b
lymphocyt
migrat
lymphoid
follicl
effector
site
typic
laminar
propria
epithelium
mucos
surfac
differenti
plasma
cell
effector
site
iga
process
epitheli
cell
secretori
iga
transport
across
epithelium
lumen
elicit
effect
multipl
way
trap
antigen
pathogen
mucu
inhibit
bacteri
adhes
mucos
surfac
neutralis
viru
extracellular
toxin
elimin
antigen
tissu
via
immun
complex
transport
mechan
epitheli
cell
enhanc
innat
immun
respons
antibodi
depend
cytotox
addit
siga
local
produc
antibodi
igm
igg
lower
respiratori
tract
igg
deriv
activ
system
adapt
immun
respons
may
also
contribut
immun
defenc
although
cytotox
prevent
pathogen
entri
crucial
clearanc
contain
viral
pathogen
infect
cell
cytotox
monitor
cell
bodi
abl
recognis
viral
antigen
present
cell
surfac
coupl
specialis
bind
protein
mhc
class
molecul
presenc
type
cytokin
eg
cytotox
induc
apoptot
destruct
infect
target
cell
therebi
also
destroy
pathogen
major
canin
vaccin
live
attenu
vaccin
although
kill
subunit
vaccin
rabi
leptospira
parenter
bb
vaccin
avail
tabl
live
attenu
vaccin
contain
version
viru
bacteria
alter
unabl
caus
seriou
clinic
diseas
howev
abl
replic
host
process
immun
system
much
way
pathogen
would
natur
infect
elicit
strong
cellular
antibodi
respons
long
durat
immun
reason
often
superior
inactiv
subunit
vaccin
especi
young
dog
matern
deriv
antibodi
mda
may
present
live
attenu
vaccin
mani
virus
rel
easi
creat
small
number
gene
easili
manipul
attenu
vaccin
often
gener
continu
cultur
viru
establish
laboratori
cell
line
typic
passag
depend
viru
viru
grow
adapt
new
environ
mutat
strain
replic
poorli
natur
host
live
attenu
vaccin
replic
within
host
requir
adjuv
situat
shed
vaccin
strain
recent
vaccin
anim
may
use
gener
herd
immun
vaccin
individu
challeng
risk
induc
diseas
immunocompromis
contact
major
disadvantag
live
attenu
vaccin
possibl
may
revert
virul
form
caus
diseas
may
unsaf
use
either
immunocompromis
pregnant
anim
viral
bacteri
pathogen
fastidi
growth
characterist
complex
genom
make
live
attenu
vaccin
difficult
creat
control
result
kill
subunit
vaccin
prefer
howev
advanc
technolog
help
address
mani
issu
except
canin
vaccin
inject
subcutan
tabl
surpris
major
vaccin
research
human
veterinari
medicin
base
larg
inject
vaccin
offer
benefit
deliv
known
quantiti
antigen
result
gener
specif
immun
respons
easili
measur
blood
serum
sampl
contrast
intranas
vaccin
face
mani
challeng
particular
need
overcom
mani
innat
immun
mechan
present
upper
airway
live
vaccin
mani
inher
properti
pathogen
facilit
infect
may
help
overcom
addit
recent
advanc
vaccin
deliveri
vehicl
also
prove
promis
situat
remain
far
ideal
studi
continu
hamper
inabl
accur
deliv
quantit
amount
deliv
antigen
veterinari
medicin
ad
issu
deliv
mucos
vaccin
safe
correctli
deliv
oral
intranas
vaccin
defens
aggress
larg
dog
trivial
problem
deliveri
intranas
vaccin
also
frequent
unpleas
outcom
snort
back
immedi
deliveri
therefor
subcutan
vaccin
surer
safer
veterinarian
nevertheless
mucos
immun
paramount
import
prevent
mani
respiratori
agent
although
publish
data
relat
canin
vaccin
develop
efficaci
limit
increas
efficaci
mucos
parenter
vaccin
bb
cpiv
shown
discuss
later
review
furthermor
face
mda
vaccin
administ
intranas
also
shown
superior
parenter
vaccin
guidelin
publish
world
small
anim
veterinari
associ
wsava
recommend
puppi
vaccin
core
vaccin
week
old
follow
booster
month
age
everi
year
thereaft
intens
vaccin
regim
first
year
life
aim
overcom
problem
surround
vaccin
efficaci
due
diverg
level
mda
individu
dog
gener
dog
respond
well
regim
numer
experiment
studi
shown
antibodi
cdv
cpv
maintain
three
year
context
cird
dog
receiv
regular
core
vaccin
puppyhood
therefor
adequ
protect
cdv
infect
two
pathogen
tradit
associ
canin
respiratori
diseas
howev
enter
kennel
facil
vaccin
histori
provid
rapid
onset
immun
vital
wsava
recommend
administ
dose
core
vaccin
upon
arriv
booster
week
later
vaccin
relev
paper
respiratori
diseas
caus
bb
cpiv
vaccin
pathogen
administ
either
subcutani
intranas
although
choic
intranas
vaccin
limit
tabl
wsava
recommend
administ
cpiv
bb
subcutan
vaccin
variou
time
point
throughout
puppyhood
adult
dog
two
dose
administ
week
apart
mani
instanc
cpiv
also
includ
compon
multival
core
vaccin
tabl
whether
administ
monoval
multival
vaccin
limit
durat
immun
offer
mean
booster
vaccin
recommend
everi
month
intranas
formul
may
administ
earli
week
age
second
dose
week
later
follow
anoth
year
adult
dog
two
dose
week
apart
recommend
booster
recommend
annual
frequent
requir
importantli
cpiv
bb
wsava
recommend
use
intranas
subcutan
vaccin
gener
consid
although
subcutan
vaccin
good
induc
system
immun
tend
rel
poor
induc
mucos
immun
convers
mucos
vaccin
shown
good
induc
mucos
system
immun
respons
although
publish
studi
canin
vaccin
extrem
limit
one
studi
compar
intranas
subcutan
bb
vaccin
dog
receiv
intranas
vaccin
higher
siga
level
nasal
secret
significantli
better
protect
challeng
virul
bb
strain
week
postvaccin
compar
dog
receiv
subcutan
bb
placebo
vaccin
experiment
studi
dog
vaccin
differ
dose
intranas
bb
vaccin
shed
vaccin
strain
detect
week
postvaccin
follow
challeng
virul
bb
clinic
sign
diseas
shed
challeng
strain
reduc
vaccin
manner
anoth
studi
compar
cpiv
intranas
parenter
vaccin
dog
vaccin
via
intranas
rout
significantli
reduc
clinic
sign
diseas
follow
challeng
furthermor
viral
shed
reduc
control
dog
dog
vaccin
via
parenter
rout
dog
vaccin
intranas
kennel
situat
speed
immun
paramount
mucos
vaccin
also
prefer
unfortun
detail
studi
relat
onset
immun
follow
subcutan
bb
vaccin
publish
howev
one
studi
examin
intranas
bb
vaccin
steadi
increas
agglutin
antibodi
titr
observ
week
postvaccin
signific
differ
observ
dog
receiv
differ
vaccin
dose
anoth
studi
vaccin
shown
induc
protect
immun
h
postvaccin
although
reason
rapid
onset
immun
determin
within
scope
studi
studi
within
field
tb
vaccin
shown
mucos
vaccin
abl
provid
immun
immedi
vaccin
stimul
innat
immun
respons
mucos
surfac
review
beverli
et
al
possibl
similar
mechan
play
date
publish
data
relat
cpiv
vaccin
efficaci
remain
extrem
limit
assess
hamper
difficulti
reproduc
diseas
laboratori
model
often
mild
neglig
uncontrol
influenc
field
studi
presenc
agent
although
result
vari
greatli
gener
consensu
publish
data
suggest
although
vaccin
cpiv
bb
reduc
rate
infect
durat
shed
sever
diseas
induc
sterilis
immun
anim
may
still
becom
infect
although
obviou
benefit
use
vaccin
incomplet
protect
elicit
import
ramif
control
erad
diseas
particularli
within
kennel
popul
assist
maintain
reservoir
pathogen
exampl
seen
studi
carri
larg
facil
three
consecut
year
studi
dog
vaccin
cpiv
upon
arriv
howev
despit
vaccin
cpiv
remain
endem
within
kennel
signific
number
dog
becom
infect
cpiv
week
postentri
busi
kennel
environ
high
turnov
dog
presenc
risk
factor
underli
cpiv
bb
infect
may
contribut
develop
sever
diseas
addit
issu
aris
efficaci
safeti
perspect
vaccin
immunocompromis
individu
particularli
rescu
kennel
environ
dog
may
immunocompromis
result
stress
malnutrit
diseas
underli
condit
tri
induc
rapid
protect
immun
respons
anim
pose
addit
challeng
leav
anim
suscept
infect
interven
period
booster
vaccin
increas
demand
quarantin
measur
safeti
perspect
use
live
attenu
vaccin
immunocompromis
individu
may
result
diseas
thu
degre
protect
elicit
vaccin
versu
potenti
problem
aris
care
consid
challeng
associ
cpiv
vaccin
efficaci
limit
vaccin
design
deliveri
despit
lack
experiment
data
long
recognis
immun
respons
natur
cpiv
infect
slow
result
sterilis
immun
leav
dog
suscept
repeat
infect
inde
similar
find
shown
human
parainfluenza
viru
piv
infect
multipl
repeat
infect
occur
immun
correl
higher
like
broadli
neutralis
antibodi
titr
although
experiment
intranas
vaccin
studi
dog
support
idea
local
mucos
immun
cpiv
infect
import
publish
data
characteris
mucos
immun
respons
cpiv
canin
host
littl
data
relat
characteris
durat
immun
respons
cpiv
serum
antibodi
follow
either
natur
experiment
infect
vaccin
also
limit
explor
genet
antigen
divers
circul
cpiv
strain
piv
speci
possess
two
major
spike
glycoprotein
one
involv
cell
attach
involv
mediat
fusion
viral
host
cell
membran
fusion
two
protein
neutralis
antibodi
target
convalesc
serum
studi
conduct
use
polyclon
serum
reveal
antigen
differ
howev
studi
limit
three
canin
isol
studi
use
monoclon
antibodi
reveal
minor
differ
hn
f
protein
although
five
isol
use
two
deriv
dog
date
six
complet
cpiv
genom
sequenc
publish
littl
addit
sequenc
data
individu
viral
gene
avail
much
base
cell
cultur
passag
isol
studi
compar
six
cpiv
genom
nine
addit
genom
differ
speci
six
human
one
simian
two
porcin
reveal
remark
divers
hn
f
gene
regardless
host
year
isol
geograph
origin
interestingli
howev
highest
degre
divers
seen
among
canin
isol
analog
human
bovin
parainfluenza
speci
possibl
divers
among
cpiv
strain
may
greater
current
studi
indic
nevertheless
author
suggest
low
level
variat
observ
indic
viru
either
particularli
immunogen
immun
import
inde
piv
evolv
numer
mechan
suppress
host
immun
respons
thu
promot
surviv
within
cell
surround
environ
although
studi
cpiv
specif
piv
speci
includ
suppress
type
ifn
potenti
mask
hn
f
protein
epitop
due
glycosyl
mention
type
ifn
princip
mediat
innat
antivir
respons
piv
evolv
rang
mechan
suppress
activ
hijack
modifi
cellular
regulatori
pathway
activ
viral
encod
protein
review
audsley
moseley
park
littl
knowledg
natur
cours
cpiv
infect
immun
respons
viru
canin
host
surpris
vaccin
capabl
produc
protect
immun
cpiv
continu
elud
us
number
novel
agent
associ
cird
continu
increas
differ
characterist
mode
pathogen
need
comprehens
investig
role
agent
within
cird
complex
interact
take
place
becom
increasingli
import
ensur
appropri
pathogen
target
vaccin
vaccin
stimul
appropri
effect
immun
respons
number
challeng
futur
dog
respiratori
vaccin
possibl
share
vaccin
veterinari
speci
human
medicin
first
increas
evid
number
newli
emerg
newli
discov
may
accur
pathogen
contribut
multicompon
diseas
complex
respiratori
diseas
although
may
appear
overwhelmingli
complic
futur
vaccin
design
awar
research
certain
viral
pathogen
abl
disabl
innat
immun
respons
therebi
facilit
superinfect
bystand
agent
case
cird
propos
certain
virus
ie
crcov
cnpnv
allow
mycoplasma
bacteria
penetr
deeper
airway
caus
clinic
diseas
futur
vaccin
design
could
focuss
prevent
earli
event
thereaft
protect
opportunist
secondari
infect
second
although
mucos
vaccin
hold
mani
benefit
debat
efficaci
compar
parenter
vaccin
remain
evid
often
effect
long
live
month
year
possibl
immedi
effect
stimul
rapidli
innat
immun
respons
give
rapid
protect
way
forward
may
prime
boost
schedul
utilis
mucos
parenter
vaccin
strategi
although
recent
studi
bb
vaccin
shown
benefici
effect
regim
requir
detail
experiment
data
understand
mucos
immun
respons
increas
alongsid
technolog
support
efficaci
mucos
vaccin
deliveri
possibl
improv
cird
vaccin
regim
nonetheless
issu
intranas
vaccin
deliveri
aggress
anim
speci
must
consid
fulli
commerci
compani
invest
develop
programm
close
ultim
decis
develop
new
vaccin
mucos
diseas
cird
complex
aetiolog
ultim
rest
pharmaceut
compani
expertis
fund
take
discoveri
novel
pathogen
rigor
demand
develop
satisfi
need
safeti
regul
licens
new
vaccin
